<DOC>
	<DOC>NCT01494584</DOC>
	<brief_summary>This is an open-label study to evaluate the pharmacokinetics, safety and tolerability of ezogabine/retigabine in subjects aged 12 years to less than 18 years with uncontrolled partial onset seizures or Lennos-Gastaut syndrome.</brief_summary>
	<brief_title>Study in Pediatric Subjects With Epilepsy</brief_title>
	<detailed_description />
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Ezogabine</mesh_term>
	<criteria>Between 12 and 18 years of age. Diagnosis of uncontrolled partial onset seizures (with or without secondarily generalized seizures) or LennoxGastaut syndrome. Taking between one and three antiepileptic drugs. Able to swallow tablets. Females must be of : (1) Nonchildbearing potential or (2) Childbearing potential and agrees to use acceptable contraception. Epilepsy secondary to progressive cerebral disease, tumor or any progressive neurodegenerative disease. History of status epilepticus in the last six months. Currently treated with felbamate or has been treated with vigabatrin within the past 6 months. Following the ketogenic diet. Suicidal intent or history of suicide attempt in the last 2 years. Elevated liver enzymes or abnormal kidney function. Current disturbance of micturition or known urinary obstructions. History of vesicoureteric reflux. Abnormal postvoid residual bladder ultrasound. Urinary retention and/or required urinary catheterization in the preceding 6 months. Abnormal urine sample at screening/.baseline. Abnormal blood sample at screening. Clinically significant arrhythmias. Abnormal ECG at screening. BMI lower than the 10th percentile for age and gender or subject weighs less than 30kg.</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>